ClinicalTrials.gg
CompletedNCT06283147Updated Oct 2, 2026

Risk Assessment and Management Program (RAMP) on Knee Osteoarthritis in Primary Care

An interventional study of Risk assessment and Management Programme - Knee Osteoarthritis in Knee Osteoarthritis, sponsored by Chinese University of Hong Kong. Completed at 1 site in Hong Kong. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Health services research

How we know

Updated Oct 2, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
228
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Osteoarthritis, Knee by Chinese University of Hong Kong — 9 open to participants now, 10 under way, none of them phase 3. Osteoarthritis, Knee · Chinese University of Hong Kong.

Enrollment
2nd of 16
228 · median 64
Started
2024
with 3 others
No phase
15 of 20
8 open now
Registered
17th of 20
by date

Among the 20 studies in Osteoarthritis, Knee by Chinese University of Hong Kong, this one is the 2nd largest by enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2024, is one of 15 with no phase, and was the 17th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

9 of the 20 studies in Osteoarthritis, Knee by Chinese University of Hong Kong are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Osteoarthritis, Knee by Chinese University of Hong Kong, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine the clinical effectiveness of a Chronic Care Model (CCM) named Risk Assessment and Management Program on Knee OA (RAMP-Knee OA) in adults with knee Osteoarthritis (Knee OA) at 52 weeks.

Participants will be screened for eligibility to participate. After confirming eligibility, participants will complete the baseline assessment and be randomized into one of the following groups (n=114 for each group):

  1. RAMP Knee-OA group
  2. Usual care group

Outcomes will be measured at baseline, week 16, week 32, and week 52.

Read the detailed description

The goal of this clinical trial is to determine the clinical effectiveness of a Chronic Care Model (CCM) named Risk Assessment and Management Program on Knee OA (RAMP-Knee OA) in adults with knee Osteoarthritis (Knee OA) at 52 weeks. RAMP-knee OA is designed based on the validated framework of CCM, which identifies six important components including self-management support, clinical information systems, delivery system redesign, decision support, health care organization, and community resources.

The main questions the study aims to answer are:

In comparison with people undergoing usual care, whether:

  • Participants in the RAMP-Knee OA group will report greater improvement in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale
  • Participants in the RAMP-Knee OA group will report greater improvement in physical function, self-management efficacy, lower limb muscle mass, psychosocial health, and quality of life

Participants will be screened for eligibility to participate. After confirming eligibility, participants will complete the baseline assessment and be randomized into one of the following groups (n=114 for each group):

  1. RAMP Knee-OA group: Participants will be referred to the RAMP-Knee OA clinic operated by a Registered Nurse, which will be a face-to-face consultation scheduled every 4 months following patients' usual clinic appointments. A total of 4 sessions will be provided for each enrolled participant over one year. The content of the Programme centers around arthritis education, structure-land base exercise, and weight management, with the additional component of counseling support and dietary advice on musculoskeletal health.
  2. Usual care group: Participants allocated to the usual care group will continue with their standard usual care (follow-up appointment at General Out Patient Clinic (GOPC) is typically every 4 months). The management approach for knee OA and other chronic diseases will be solely at the discretion of the attending physicians.

Outcomes will be measured at baseline, week 16, week 32, and week 52. Demographic data and knee pain duration will be collected at baseline assessment. Outcomes to measure include the severity of knee pain, physical function, level of physical activity, self-efficacy, level of anxiety and depression, insomnia, loneliness, health-related quality of life, and lower limb muscle mass. The use of co-intervention, analgesics, and other over-the-counter drugs will be recorded.

The baseline characteristics of the two groups will be compared using the independent samples t-test or the Mann-Whitney test for continuous variables and chi-square test for categorical variables.

03

Conditions studied

  • Knee Osteoarthritis

Keywords

  • Risk assessment and Management Programme
  • Chronic Care Model
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Knee OA based on clinical criteria of the American Rheumatology College
  • Moderate to severe Knee pain for 3 months or longer (average score of 4 or greater on a 0-10 pain scale in the past 3 months)

Exclusion criteria

Exclusion Criteria:

  • Participants with potential serious knee pathology (e.g. inflammatory arthritis, acute trauma, )
  • Previous Knee replacement
  • Scheduled knee joint replacement surgery within 1 year
  • Participants who are unable to reliably participate (e.g. those who do not speak Chinese or unable to attend study intervention)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
228 participants (actual)

Study arms

  • Experimental
    RAMP Knee OA

    Patients allocated to the intervention group will continue their "usual care" at the GOPCs, plus enrolment into the RAMP-Knee OA program.

    Behavioral: Risk assessment and Management Programme - Knee Osteoarthritis

  • No intervention
    Usual Care group

    Patients allocated to the usual care arm will continue receiving their "usual care" at the GOPCs without any additional intervention. "Usual care" typically refers to the established and commonly provided treatments, interventions, and practices that patients would receive in routine clinical practice for their particular condition or disease. For GOPCs in Hong Kong, the follow-up period for all chronic diseases is typically every 4 months. Each consultation at GOPC has an average duration of 3-5 minutes, during which physicians will address all chronic diseases, including knee OA. Physicians may provide brief healthcare advice, prescribe chronic medications and analgesics if necessary, and refer patients to physiotherapy if indicated. The management approach for knee OA and other chronic diseases will be solely at the discretion of the attending physicians.

Interventions

  • BehavioralRisk assessment and Management Programme - Knee Osteoarthritis

    (i) Arthritis education: Topics will cover the 21 key messages identified in International Consensus List of Essential Statements for Osteoarthritis "What Do People With Knee or Hip Osteoarthritis Need to Know" (ii) Structured land-based exercise: We have selected strengthening, flexibility training (stretching), and aerobic exercise as our key components because they are most applicable in primary care settings. (iii) Weight Management: Weight management will be offered for participants with a BMI ≥ 23 kg/m2. (iv) Counselling support for psychosocial health: counselling support will be provided for those with mild to moderate anxiety and depression, insomnia and loneliness identified in the risk assessment. (v) Dietary advice: Online dietary education for musculoskeletal health (with reference to local context) will be provided. The dietitian will also provide support regarding specific dietary advice on weight management.

06

What researchers measure

Primary outcomes

  1. Knee pain

    Knee pain as measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)

    Time frame: Baseline, week 16, week 32, week 52

Secondary outcomes

  1. Physical Function

    Physical function measured by WOMAC function subscale

    Time frame: Baseline, week 16, week 32, week 52

  2. Physical function

    Physical function measured by 30-second chair and stand performance test

    Time frame: Baseline, week 16, week 32, week 52

  3. Lower limb muscle mass

    Lower limb muscle mass measured by bio-impedance analysis

    Time frame: Baseline, week 16, week 32, week 52

  4. Level of physical activity

    Level of physical activity measured by Chinese International Physical Activity Questionnaire (Short form)

    Time frame: Baseline, week 16, week 32, week 52

  5. Self-Management efficacy

    Self-management efficacy measure by Pain-Self Efficacy questionnaire

    Time frame: Baseline, week 16, week 32, week 52

  6. Level of Anxiety

    Anxiety measured by Generalized Anxiety Disorder -7

    Time frame: Baseline, week 16, week 32, week 52

  7. Level of Depression

    Depression measured by Patient Health Questionnaire -9

    Time frame: Baseline, week 16, week 32, week 52

  8. Insomnia

    Insomnia measured by 7 item Insomnia Severity Index

    Time frame: Baseline, week 16, week 32, week 52

  9. Loneliness

    Loneliness measured by 6 item De Jong Gierveld Loneliness Scale

    Time frame: Baseline, week 16, week 32, week 52

  10. Health related Quality of Life

    Health related Quality of life measured by Euroquol- 5D-5L

    Time frame: Baseline, week 16, week 32, week 52

  11. Demographic data

    Demographic data such as height, weight, BMI, age, sex, knee pain duration, chronic comorbid conditions, chronic medications

    Time frame: Baseline

07

Study locations

1 site
  • Lek Yuen GOPC
    Hong Kong, Hong Kong
08

References and documents

Publications

  • Sit RW, Yip BH, Choi SY, Wong MC, Law SW, Lam CY, Hunter D, Wong SY. Risk Assessment and Management Program (RAMP) on knee osteoarthritis in primary care-a one-year pragmatic randomized controlled trial. Trials. 2026 Feb 3;27(1):187. doi: 10.1186/s13063-026-09469-x. PubMed 41629997 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in May 2026, 25 months.

Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's 25 months is above that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Nov 2025 → May 2026 and completion Apr 2026 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2024
First posted
Feb 28, 2024
StartActual
Apr 8, 2024
Primary completionActual
May 30, 2026was Nov 2025
CompletionActual
Jun 30, 2026was Apr 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 2, 2026
Primary completion
Nov 30, 2025→May 30, 2026 (actual)
Oct 2, 2026
Study completion
Apr 1, 2026→Jun 30, 2026 (actual)
Oct 2, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41629997 ↗
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Active, not recruiting→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41629997 ↗
    Primary completion Nov 30, 2025→May 30, 2026 (now actual)
    Study completion Apr 1, 2026→Jun 30, 2026 (now actual)
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06283147
Responsible party
Regina Wing Shan Sit (Professor Regina Wing Shan Sit, Chinese University of Hong Kong) — Principal investigator
First posted
Feb 28, 2024
Start date
Apr 8, 2024
Primary completion
May 30, 2026
Completion
Jun 30, 2026
Last update
Oct 2, 2026

Study contacts

Regina Wing Shan SIT, M.D.
principal investigator · Jockey Club School of Public Health and Primary Care, Chinese University of Hong Kong

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion